Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

12,574 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H, Shimodaira H, Fujitani K, Takashima A, Yamaguchi K, Nakayama N, Takahashi T, Oki E, Azuma M, Nishina T, Hironaka S, Komatsu Y, Shitara K. Bando H, et al. Among authors: Takahashi T. Eur J Cancer. 2018 Mar;91:86-91. doi: 10.1016/j.ejca.2017.11.032. Epub 2018 Jan 30. Eur J Cancer. 2018. PMID: 29353164 Clinical Trial.
Complicated puzzle in cetuximab-based chemotherapy: skin toxicity and resection rate in patients with initially unresectable colorectal liver metastases.
Sunakawa Y, Takahashi T, Ichikawa W, Shimada K, Sasaki Y. Sunakawa Y, et al. Among authors: Takahashi T. J Clin Oncol. 2013 Dec 10;31(35):4473. doi: 10.1200/JCO.2013.50.8713. Epub 2013 Oct 28. J Clin Oncol. 2013. PMID: 24166514 No abstract available.
Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.
Sunakawa Y, Yang D, Moran M, Astrow SH, Tsuji A, Stephens C, Zhang W, Cao S, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Masuishi T, Takeuchi M, Fujii M, Nakajima T, Ichikawa W, Lenz HJ. Sunakawa Y, et al. Among authors: Takahashi T. Cancer Biol Ther. 2016 Jul 2;17(7):751-9. doi: 10.1080/15384047.2016.1178426. Epub 2016 Apr 22. Cancer Biol Ther. 2016. PMID: 27104867 Free PMC article.
Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
Ichikawa W, Ooyama A, Toda E, Sugimoto Y, Oka T, Takahashi T, Shimizu M, Sasaki Y, Hirayama R. Ichikawa W, et al. Among authors: Takahashi T. Cancer Chemother Pharmacol. 2006 Dec;58(6):794-801. doi: 10.1007/s00280-006-0217-6. Epub 2006 Mar 10. Cancer Chemother Pharmacol. 2006. PMID: 16528528
Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.
Satoh E, Sasaki Y, Ohkuma R, Takahashi T, Kubota Y, Ishida H, Hamada K, Kiuchi Y, Tsunoda T. Satoh E, et al. Among authors: Takahashi T. Cancer Sci. 2018 Dec;109(12):3896-3901. doi: 10.1111/cas.13831. Epub 2018 Nov 27. Cancer Sci. 2018. PMID: 30315613 Free PMC article.
Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.
Sunakawa Y, Yang D, Cao S, Zhang W, Moran M, Astrow SH, Hsiang J, Stephens C, Tsuji A, Takahashi T, Tanioka H, Negoro Y, Takagane A, Tani S, Yamaguchi T, Eto T, Fujii M, Ichikawa W, Lenz HJ. Sunakawa Y, et al. Among authors: Takahashi T. Clin Colorectal Cancer. 2018 Dec;17(4):e741-e749. doi: 10.1016/j.clcc.2018.08.002. Epub 2018 Aug 23. Clin Colorectal Cancer. 2018. PMID: 30219280 Free PMC article.
In addition, 2-sample t tests were performed to investigate which genes among the top 100 genes associated with survival had significantly different expression levels between the NLR-low and NLR-high groups among all measured genes. ...The 2-sample t test revealed that the expression levels of the LYZ, TYMP, and CD68 genes differed significantly between the NLR-low and NLR-high groups (t test P-value < .005; false discovery rate P-value < .15). ...
In addition, 2-sample t tests were performed to investigate which genes among the top 100 genes associated with survival had signific …
12,574 results
Jump to page
Feedback